Class summary at a glance.

Every drug in the Echinocandin Antifungal class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $13.5Mcombined across class
Total Rx claims: 33K9K unique beneficiaries
Generic mfrs (active): 14across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Micafungin

Brand: Micafungin · 26K Part D claims (CY24) · 7K beneficiaries · First FDA approval: 2005-03-16

10 generic mfrs 8 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $10.4M

Class share

77%

of class CY24 spend

View profile →

Caspofungin

Brand: CANCIDAS · 5K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2001-01-26

4 generic mfrs 62 plans require PA Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $2.1M

Class share

15%

of class CY24 spend

View profile →

Anidulafungin

Brand: ERAXIS · 712 Part D claims (CY24) · 184 beneficiaries · First FDA approval: 2006-02-17

Brand-only (no generics) 17 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $635458

Class share

of class CY24 spend

View profile →

Rezafungin

Brand: REZZAYO · 130 Part D claims (CY24) · 42 beneficiaries · First FDA approval: 2023-06-09

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $370235

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.